Angiogenesis pp 245-252 | Cite as

Angiogenesis and Fibrin Degradation in Human Breast Cancer

  • W. D. Thompson
  • J. E. H. Wang
  • S. J. Wilson
  • N. Ganesalingam
Part of the NATO ASI Series book series (NSSA, volume 263)


Poorer prognosis and likelihood of metastasis in patients with breast cancer have now been claimed by several groups to be associated with increased vascularity in breast biopsies from these cases (1, 2, 3). Fibrin deposition and lysis is known to occur at the invasive tumour margin of breast cancer where angiogenesis also occurs. Fibrin degradation products (FDP) have been shown previously by us to be angiogenic on the standard test system, the chick chorioallantoic membrane (CAM) (4). Solid fibrin is degraded by plasmin into soluble combinations of the two major components termed D and E, and it is fragment E that is angiogenic (5). Therefore our aim was to develop a method for assessing individual tumour angiogenic activity, and to relate this to tumour vascularity and content of FDP (6).


Angiogenic Activity Fibrin Degradation Product Human Atherosclerotic Plaque Chick Chorioallantoic Membrane Aberdeen Royal Infirmary 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weidner N, Semple JP, Welch WR Folkman J. Tumour angiogenesis and metastasis - correlation in invasive breast carcinoma. New Eng J Med 1991; 324: 1 - 8PubMedCrossRefGoogle Scholar
  2. 2.
    Bosari S, et al. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755 - 761.PubMedCrossRefGoogle Scholar
  3. 3.
    Horak ER et al. Angiogenesis, assessed by platelet/ endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120 - 1124.PubMedCrossRefGoogle Scholar
  4. 4.
    Thompson WD, Campbell R, Evans T. Fibrin degradation and angiogenesis: quantitative analysis of the angiogenic response in the chick chorioallantoic membrane. J Pathol 1985; 145: 27 - 37.PubMedCrossRefGoogle Scholar
  5. 5.
    Thompson WD, Smith EB, Stirk CM, Marshall FI, Stout AJ, Kocchar A. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J Pathol 1992; 168: 47 - 53.CrossRefGoogle Scholar
  6. 6.
    Wang JEH, Wilson SJ, Thompson WD. Fibrin degradation and angiogenesis in human breast cancer. J Pathol 1993; 169 S, 178 (Abs).Google Scholar
  7. 7.
    Smith EB, Keen GA, Grant A. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263 - 275.PubMedCrossRefGoogle Scholar
  8. 8.
    Thompson WD, Brown FI. Quantitation of histamine-induced angiogenesis in the chick chorioallantoic membrane: mode of action of histamine is indirect. Int J Microcirc 1987; 6: 343 - 357.Google Scholar
  9. 9.
    Clinton M, Duncan JI, Long WF, Williamson FB, Thompson WD. Effect of mast cell activator, Compound 48/80, and heparin on angiogenesis in the chick chorioallantoic membrane. Int J Microcirc. 1988; 7: 315 - 326.Google Scholar
  10. 10.
    Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T. Nature 1970; 227: 680 - 685.PubMedCrossRefGoogle Scholar
  11. 11.
    Thompson WD, Harvey JA, Kazmi MA, Stout AJ. Fibrinolysis and angiogenesis in wound healing. J Pathol 1991; 165: 311 - 318.PubMedCrossRefGoogle Scholar
  12. 12.
    Thompson WD, McGuigan CJ, Snyder C, Keen GA, Smith EB. Mitogenic activity in human atherosclerotic lesions. Atherosclerosis 1987 66: 85 - 93.PubMedCrossRefGoogle Scholar
  13. 13.
    Thompson WD, Smith EB, Stirk CM, Kochhar A. Atherosclerotic plaque growth: presence of stimulatory fibrin degradation products. Blood Coagulation and Fibrinolysis 1990; 1: 489 - 493PubMedCrossRefGoogle Scholar
  14. 14.
    Kamat BR, Galli SJ, Barger AC, Lainey LL, Silverman KJ. Neovascularization and coronary atherosclerotic plaque: cinematic localization and quantitative histologic analysis. Hum Pathol 1987; 18: 1036 - 1042.PubMedCrossRefGoogle Scholar
  15. 15.
    Schwartz SM. Serum-derived growth factor is thrombin? J Clin Invest 1993; 91: 4.PubMedCrossRefGoogle Scholar
  16. 16.
    Sarembok LT, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desuphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232 - 243CrossRefGoogle Scholar
  17. 17.
    Thompson WD, Harvey JA, Kazmi MA, Stout AJ. Fibrinolysis and angiogenesis in wound healing. J Pathol 1991; 165: 311 - 318.PubMedCrossRefGoogle Scholar
  18. 18.
    Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev 1990; 70: 1177 - 1209.PubMedGoogle Scholar
  19. 19.
    Flaumenhaft R, Rifkin DB. The extracellular regulation of growth factor action. Molec Biol Cell 1992; 3: 1057 - 1065.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • W. D. Thompson
    • 1
  • J. E. H. Wang
    • 1
  • S. J. Wilson
    • 1
  • N. Ganesalingam
    • 1
  1. 1.Department of Pathology, Medical SchoolAberdeen Royal InfirmaryAberdeenUK

Personalised recommendations